期刊文献+

抗肿瘤多肽HM-3的中和抗体活性研究

Research of anti-tumor peptide neutralizing antibodies activities
下载PDF
导出
摘要 本研究检测抗肿瘤多肽HM-3在SD大鼠和食蟹猴长期毒性实验血清中中和抗体的产生及抗体活性的强弱。将SD大鼠与食蟹猴分别分成4.5,13.5,40.5mg/kg和3,9,27mg/kg3个剂量组,均每日静脉注射HM-3多肽1次,均连续给药6个月。每月取血清用ELISA法测定滴度,并用细胞迁移法测定抗体中和活性。长期给药过程中,中高剂量组的SD大鼠能产生抗体,其中少数检测到中和抗体的活性(P<0.05),而食蟹猴中能产生抗体的数量较少,且其中只有个别食蟹猴的血清中能检测到中和抗体的产生(P<0.05)。且抗体滴度与中和抗体活性不呈正相关。由此,本研究认为HM-3的抗原性较低,长期高剂量给药后极个别会产生一些低亲和力的中和抗体。 The generation and activity of serum neuralizing antibody in cynomolgus monkeys and SD rats undergoing long-term toxicity study with antitumor peptides HM-3 were investigated.The rats were administered intravenously with HM-3 at doses of 4.5 mg/kg,13.5 mg/kg,and 40.5 mg/kg for 6 months,and the cynomolgus monkeys were administrated intravenously with HM-3 at doses of 3 mg/kg,9 mg/kg and 27 mg/kg for 6 months,respectively.Anti-HM-3 antibodies and their neutralizing activities in serum samples taken every month after the administrations were determined by ELISA and cell migration assay,respectively.During the long-term administrations,anti-HM-3 antibodies were generated in some SD rats at high and moderate dose groups,and the anti-body-neutralizing activities could be detected in a number of these samples (P〈0.05).However,activity could be detected in very few monkeys (P〈0.05),and the antibody titers were not correlated with the neutralizing activities.Therefore,we conclude that the antigenicity of HM-3 was low,but after long-term administration at high dose,low affinity neutralizing antibody could be generated in small number of samples.
出处 《中国药科大学学报》 CAS CSCD 北大核心 2010年第2期171-174,共4页 Journal of China Pharmaceutical University
基金 国家"重大新药创制"科技重大专项资助项目(No.200909102-244)~~
关键词 抗肿瘤多肽HM-3 长期毒性 中和抗体 antitumor peptides HM-3 long-term toxicity study neutralizing antibody
  • 相关文献

参考文献7

  • 1Porter S. Human immune response to recombinant human proteins [J].J Pharm Sci,2001,90(1) :1 - 11.
  • 2Stein KE. Immunogenicity: concepts/issues/concerns [ J]. Dev Biol(Basel) ,2002,109 : 15 - 23.
  • 3Mire-Sluis AR,Barrett YC, Devanarayan V,et al. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnolog) products[ J]. J Immunol Methods ,2004,289 ( 1-2 ) : 1 - 16.
  • 4Gupta S, Indelicato SR, Jethwa V,et al. Recommendations for the design,optimization, and qualificalion of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics [ J ]. J Immunol Methods, 2007,321 ( 1-2 ) : 1 -18.
  • 5Kessler M, Goldsmith D,Schellekens H. hnmunogenicity of biopharmaceuticals [ J ]. Nephrol Dial Transplant,2006,21 ( Suppl ) : 9 - 12.
  • 6Wadhwa M, Bird C, Dilger P,et al. Strategies for detection, measurement and characterization of unwanted antibodies induced by therapeutic biological[ J]. J lmmunol Methods ,2003,278 ( 1-2 ) : 1 -17.
  • 7徐冰,李岱,詹小玲,刘金花,许杨华.重组集成干扰素α在不同动物长期毒性实验血清中中和抗体的产生及活性研究[J].中国药房,2006,17(18):1373-1375. 被引量:5

二级参考文献9

  • 1[1]Antonelli G,Gurrenti M,Turriziani O,et al.Neutralizing antibodies to interferon-α:relative frequency in patients treated with different interferon preparations[J].J Infect Dis,1991,163:882.
  • 2[2]周海钧主译.ICH药品注册国际技术要求[M].北京:人民卫生出版社,2001:121.
  • 3[3]Antonelli G,Giannelli G,Currenti M,et al.Antibodies to interferon (IFN) in hepatitis C patients relapsing while continuing recombinant IFN-alpha2 therapy[J].Clin Exp Immunol,1996,104(3):384.
  • 4[4]Milella M,Antonelli G,Santantonio T,et al.Treatment with natural IFN of hepatitis C patients with orwithout antibodies to recombinant IFN[J].Hepatogastroenterology.1995,42(3):201.
  • 5[5]Milella M,Antonelli G,Santantonio T,et al.Neutralizing antibody to re-combinant alpha interferon and response to therapy in chronic hepatitis C virus infection[J].Liver,1993,13(3):146.
  • 6[8]Ozes ON,Reiter Z,Klein S,et al.A comparison of interferon-con 1 with natural recombinant interferons-α:antiviral,antiproliferative,and natural killer-induceing activities[J].J Interferon Res,1992,12(1):55.
  • 7[9]Tong MJ,Blatt LM,Resser KJ,et al.Treatment of chronic hepatitis C virus infection with recombinant consensus interferon[J].J Interferon and Cytokine Res,1998,18(1):81.
  • 8童福易,唐永煌,白敬羽.α干扰素中和抗体对慢性病毒性肝炎疗效的影响[J].中华实验和临床病毒学杂志,1999,13(4):345-347. 被引量:5
  • 9毛乾国,骆抗先,刘定立,张明霞,侯金林.干扰素中和抗体对慢性乙型肝炎抗病毒应答的影响[J].中华肝脏病杂志,2004,12(4):205-207. 被引量:13

共引文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部